NCT01208753View on ClinicalTrials.gov

Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

February 28, 2011

Conditions
Healthy
Interventions
DRUG

GLPG0555

two different aqueous formulations

DRUG

GLPG0555 aqueous

multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined

DRUG

placebo

multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule

Trial Locations (1)

Unknown

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY